And its wholly owned subsidiary, Marvel Biotechnology Inc, announces that it has initiated the 4-week good laboratory practice FDA investigational new drug enabling dose-ranging dog studies for its lead drug candidate MB-204. "We look forward to the completion of the rat and dog GLP studies of MB-204, and entering human trials, prior to the end of Q3 2023," said Rod Matheson, CEO of Marvel Biosciences. "We believe the profile of MB-204 is well-suited to address our primary markets, specifically depression and Alzheimer's disease. Owing to the immediate effect of the compound, we are confident that it will show the active effects early on in our clinical program." Marvel Biosciences Corp shares V.MRVL are trading down one cent at $0.09.